EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.
about
Heme controls the regulation of protein tyrosine kinases Jak2 and SrcSignaling cross-talk in the resistance to HER family receptor targeted therapyMolecular Mechanism of Selectivity among G Protein-Coupled Receptor Kinase 2 InhibitorsQuantification and kinetic analysis of Grb2-EGFR interaction on micro-patterned surfaces for the characterization of EGFR-modulating substancesThe Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor.Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.Exons 19 and 21 of epidermal growth factor receptor are highly conserved in squamous cell cancer of the head and neckDown-regulation of miR-214 reverses erlotinib resistance in non-small-cell lung cancer through up-regulating LHX6 expression.A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation.Nuclear trafficking of the epidermal growth factor receptor family membrane proteins.Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity.Notch-EGFR/HER2 Bidirectional Crosstalk in Breast CancerSquamous Cell Carcinoma - Similarities and Differences among Anatomical Sites.The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumorsOncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perilsRisk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy.Personalized targeted therapy for lung cancerThe use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer.A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group studyRapid induction of lung adenocarcinoma by fibroblast growth factor 9 signaling through FGF receptor 3.EGFR Inhibition in the Treatment of Non-Small Cell Lung CancerConcordance of anaplastic lymphoma kinase (ALK) gene rearrangements between circulating tumor cells and tumor in non-small cell lung cancer.Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cells.EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer.Protein kinase inhibitors: contributions from structure to clinical compounds.Oncogene mutational profile in nasopharyngeal carcinoma.Targeting epidermal growth factor receptor in the treatment of non-small-cell lung cancer.Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer.That which does not kill me makes me stronger; combining ERK1/2 pathway inhibitors and BH3 mimetics to kill tumour cells and prevent acquired resistance.Next-generation sequencing for lung cancer.EGFR signaling and autophagy dependence for growth, survival, and therapy resistance.Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting.Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer.Curcumin sensitizes human lung cancer cells to apoptosis and metastasis synergistically combined with carboplatin.EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.Design and Synthesis of 4-Anilinothieno[2,3-d]pyrimidine-Based Compounds as Dual EGFR/HER-2 Inhibitors.In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells.6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.
P2860
Q24305018-4380B519-391A-4720-8F51-CC5ECCBAB652Q27027778-02F8AE1F-5274-4A48-B740-D3A04EFD24C2Q27667904-6A5F588B-8AA7-4C47-9D06-37DF05585497Q28541305-B55C5616-17ED-4C55-BDA8-AC11031DE77BQ30009944-725EE819-3A5C-477C-9366-DC2AD4DF0DF6Q33574627-34642F8B-49E7-48F0-8344-CE29CD60E085Q33621754-7BD2F276-75E0-4229-9C3C-8FB5AF86D1E0Q33677872-5036B442-3FC0-45BB-BDF6-B5E0D0B9A46BQ33699169-0124CFC8-8E3F-4746-A3A9-87C65B248182Q33944679-D8DE977F-D633-4AE7-B886-AE02A96F7FC3Q33998459-99EAFB3F-6A53-488E-9FAE-11FEBE45D57EQ34042708-C26DC51E-148F-4F23-B9CA-FD3019C99BF7Q34686900-70F1C0BE-0C47-414D-B4B1-154A8D198B99Q35220347-249D8654-F9BA-42B9-AF55-9D94D12D39F6Q35800375-90125167-D666-4FFD-982D-A28BAEF14487Q36025680-6A6699FD-514D-49C5-BE6F-94D1E0FDB352Q36038823-84901EFC-138B-4FB9-BD01-32E17240A36FQ36306292-E454BEA2-F00E-4EE7-98AD-B5FA26E8948CQ36321826-4CD55D14-8CE0-4A44-ABF7-4C3A5ED90E54Q36928853-B4852068-1395-44C1-A597-F52614EDA629Q36980484-ACB39FEB-8E8C-4E7E-A69C-3DF09A678B7DQ37185267-E9F9B24D-C6ED-49E6-822B-1872E16F02B2Q37240726-F6EC08C0-DA70-47FF-9915-F23C7F8E2B3FQ37268985-A22D7415-1172-445A-AAF7-2B510B1769CCQ37375271-9C8988BD-AED6-4D5B-9750-27C72C90252AQ37408809-24525ECB-0CB6-49AE-8483-BD7B05E504E1Q37417742-49DCE73E-D092-4017-889E-D7634343BD7EQ37660226-7A4CF15B-F00E-4384-AAC5-9AC33013FD8FQ37768460-C92A770C-6D85-46FB-9067-26481C2E3763Q37853481-D8AD707E-9EC3-4EB2-8F79-E591AC74FE07Q38104439-80B9B97E-24E7-4E9E-B18E-7620FFBA117DQ38131798-B7205F3A-2D7E-40D3-AC7D-9ED7F6E212E1Q38171032-23749871-A736-4423-9CE1-A9AF002693FFQ38187388-9DFC46CE-62B7-4DAC-8479-DB2AE1482A12Q38219688-30E560A2-2AD4-4D06-8186-86D0E8976308Q38428287-4B408A97-F92C-41B9-8EAD-AF1A65FD48FCQ38609721-8B5AC5DD-724E-44F2-86BC-E7CEF7C91264Q38734275-771F0495-BE57-4D0B-93EC-265FCE98B157Q38936986-6F524EEC-C7D9-4CF2-B364-B3F5BDFAB06BQ39126918-623B10F8-6353-4FB4-A116-73F4A16E3A08
P2860
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.
@en
type
label
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.
@en
prefLabel
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.
@en
P1476
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.
@en
P2093
Lecia V Sequist
Thomas J Lynch
P304
P356
10.1146/ANNUREV.MED.59.090506.202405
P577
2008-01-01T00:00:00Z